Lisa A. Carey, MD, and Mark E. Robson, MD, on HER2-Negative Breast Cancer: Results From the OlympiAD Trial
2017 ASCO Annual Meeting
Lisa A. Carey, MD, of the University of North Carolina, and Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, discuss phase III study findings on olaparib monotherapy vs chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation. (Abstract LBA4)
John Marshall, MD, of Georgetown University, and John Neil Primrose, PhD, MBBS, of the University of Southampton, discuss the potentially practice-changing findings on adjuvant capecitabine for biliary tract cancer. (Abstract 4006)
Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.
Temidayo Fadelu, MD, of Dana-Farber Cancer Institute, discusses study findings on nut consumption and survival in stage III colon cancer patients. Higher consumption of nuts may be associated with significantly reduced cancer recurrence and death in this group. (Abstract 3517)
David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and pediatric cancers. (Abstract LBA2501)
Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)